Skip to content

IMR Evaluation in Patients with Coronary Sinus Reducer Implantation (INROAD Study)

Index of Microcirculatory Resistance Evaluation in Patients with Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina Pectoris, the INROAD Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05174572
Acronym
INROAD
Enrollment
21
Registered
2021-12-30
Start date
2021-12-03
Completion date
2025-02-11
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Angina Pectoris

Keywords

Angina, Microcirculation resistance, Coronary sinus Reducer

Brief summary

The INROAD is an investigator-driven, prospective, study in which patients undergoing coronary sinus reducer implantation (Reducer) for chronic refractory angina undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up

Detailed description

Refractory angina (RA) is a chronic condition (present for at least 3 months) of moderate-severe symptoms (Canadian class Cardiovascular Society \[CCS\] II-IV) due to coronary artery disease which cannot be adequately controlled by the combination of optimal medical therapy and coronary revascularization. The clinical impact in terms of quality of life, re-hospitalization and socio-health costs is extremely negative. In this context, the therapeutic goals are primarily the management of the symptom and improvement the patient's quality of life. The unpaid therapeutic demand of these patients has brought out a large number of medical and interventional treatments, including the coronary sinus reduction system (REDUCER). Numerous clinical studies and registries have been carried out and they proved both the efficacy and safety in the use of REDUCER. The physiological mechanism that are supposed to be behind the antianginal effect of coronary sinus intervention are essentially two: 1. Redistribution of coronary flow from the subepicardium to the subendocardium. 2. Coronary neoangiogenesis In both cases, the primum movens of the Reducer's therapeutic mechanism is attributable to the increase in venous pressure due to narrowing of the coronary sinus. Nevertheless, this mechanism of action is theoretical and has never been objectively tested. The evaluation of microcirculatory resistance by IMR before and after REDUCER implantation could be the most effective way to confirm this hypothesis.

Interventions

PROCEDUREIMR

Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.

Sponsors

Consorzio Futuro in Ricerca
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old * Chronic refractory angina refractory to medical and interventional therapies. * At least one open coronary artery (excluded right coronary artery) where to performs IMR evaluation * Ability to provide informed written consent * Life expectancy ≥1 year

Exclusion criteria

* Recent (within 3 months) acute coronary syndrome * Left ventricular ejection fraction of \<30% * Severe valvular heart disease * Inability to perform IMR * Technical contraindications to the implant ( A pacemaker electrode in the coronary sinus, Mean right atrial pressure \>15mmHg, Anomalous coronary sinus anatomy)

Design outcomes

Primary

MeasureTime frameDescription
Change in IMR value4 month after Reducer implantationSignificant Change (≥ 20%) in index of microcirculatory resistance (IMR) value at 4 month follow-up as compared to baseline value (before Reducer implantation). The IMR is calculated by multiplying the distal coronary pressure by the mean transit time of a 3 ml bolus of saline at room temperature during coronary hyperaemia induced by intravenous adenosine. Normal values are usually reported as ≤25.

Secondary

MeasureTime frameDescription
Change in Canadian Cardiovascular Society angina class a4 month after Reducer implantationChange in Canadian Cardiovascular Society (CCS) angina class by two or more classes after Reducer implantation. The CCS evaluation is performed before the Reducer implantation and after 4 months. A CCS angina class I: ordinary activity such as walking or climbing stairs does not precipitate angina. CCS II : angina precipitated by emnotion, cold weather or meals and by walking up stairs-. CCS III: marked limitation of ordinary physical activity. CCS III indicate a worst clinical situation.
Change in Beck depression inventory4 month after Reducer implantationChange in Beck depression inventory (BDI) scale after Reducer Implantation. The questionnaire is performed before the Reducer implantation and after 4 months. A BDI scores from 0 through 9 indicate no or minimal depression; scores from 10 through 18 indicate mild to moderate depression; scores from 19 through 29 indicate moderate to severe depression; and scores from 30 through 63 indicate severe depression.A BDI of 63 indicate a worst clinical situation.
Change in CFR (coronary flow reserve)4 month after Reducer implantationChange in CFR (coronary flow reserve) value after Reducer Implantation. The CFR is performed before the Reducer implantation and after 4 month. CFR is defined as hyperemic coronary flow divided by resting flow and can be measured invasively in the catheterization laboratory with a cut-off of normality ≥ 2.0.
Change in angina severity according to the Seattle Angina Questionnaire4 month after Reducer implantationChange in angina severity according to the Seattle Angina Questionnaire (SAQ) after Reducer implantation. The questionnaire is performed before the Reducer implantation and after 4 months. The scores on the SAQ angina frequency scale of 0-30 points indicate daily angina, 31-60 points indicate weekly angina, 61-99 points indicate monthly angina, and 100 points indicate no angina. Zero at SAQ indicate a worst clinical situation.
Change in LVEDP (left ventricular end-diastolic pressure)4 month after Reducer implantationChange in LVEDP (left ventricular end-diastolic pressure) after Reducer implantation. LVEDP is performed before Reducer implantation and after 4 month. The LVEDP is measure 50 ms after the beginning of the QRS complex, usually coinciding with the R wave. The normal LVEDP cut-off is 15 mmHg.
Change in Speckle tracking echocardiography (STE) value4 month after Reducer implantationChange in Speckle tracking echocardiography (STE) value after Reducer implantation
Change in RRR (resistive reserve ratio) value4 month after Reducer implantationChange in RRR (resistive reserve ratio) value after Reducer implantation. The RRR is performed before Reducer implantation and after 4 month. RRR was calculated as the ratio between resting and hyperemic distal coronary pressure (\[resting Tmn/hyperemic Tmn\] × \[resting Pd/ hyperemic Pd\]); which can therefore be simplified as the relationship between CFR x \[resting Pd/ hyperemic Pd\]. Cut-off values of normality is \> 3.5.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026